Indication · To treat refractory, metastatic colorectal cancer

To treat refractory, metastatic colorectal cancer FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 1 To treat refractory, metastatic colorectal cancer drug. 1 FDA approval recorded, most recently FRUZAQLA® (fruquintinib) on November 8, 2023.

Drugs

DrugSponsorModalityDesignations
FRUZAQLA® (fruquintinib)TAKsmall_moleculeBreakthrough Therapy, Priority Review

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
November 8, 2023FRUZAQLA® (fruquintinib)TAKFDA approvalTo treat refractory, metastatic colorectal cancerApprovedSEC 8-K Exhibit 99.1

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.

Questions

What To treat refractory, metastatic colorectal cancer drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.